Cytokinetics
CYTK
134 hedge funds and large institutions have $502M invested in Cytokinetics in 2019 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 70 increasing their positions, 23 reducing their positions, and 18 closing their positions.
671% more call options, than puts
Call options by funds: $7.07M | Put options by funds: $917K
204% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 23
55% more capital invested
Capital invested by funds: $324M → $502M (+$178M)
4.5% more ownership
Funds ownership: 72.87% → 77.37% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3% less funds holding
Funds holding: 138 → 134 (-4)
11% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 18
Top Buyers
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$21.1M |
| 2 |
BI
BVF Inc
San Francisco,
California
|
+$13.3M |
| 3 |
Millennium Management
New York
|
+$10M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.85M |
| 5 |
State Street
Boston,
Massachusetts
|
+$3.61M |
Top Sellers
CYTK Hedge Fund Activity: Q2 2019 in Review
134 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q2 2019, worth a combined $502M — up 55% from $324M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CYTK and 16 opened new positions — a net loss of 2 holders — while 23 trimmed existing stakes and 70 added.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $21.1M. The largest seller was Lansdowne Partners (UK), exiting entirely with an estimated $11.8M sold.
- 134 institutional investors held Cytokinetics (CYTK) as of Q2 2019, down from 138 in Q1 2019.
- Funds reported $502M of Cytokinetics stock for Q2 2019, up 55% quarter-over-quarter.
- 16 funds opened new Cytokinetics positions in Q2 2019 and 18 closed out, a net change of -2 holders.
- The largest Cytokinetics buyer in Q2 2019 was Driehaus Capital Management, an estimated $21.1M added.
- The largest Cytokinetics seller in Q2 2019 was Lansdowne Partners (UK), an estimated $11.8M sold.
Based on aggregated 13F filings for Q2 2019.